Intelligent Bio Solutions’ (INBS) Sell (E+) Rating Reiterated at Weiss Ratings

Intelligent Bio Solutions (NASDAQ:INBS)‘s stock had its “sell (e+)” rating reaffirmed by research analysts at Weiss Ratings in a report released on Wednesday,Weiss Ratings reports.

Separately, Wall Street Zen downgraded Intelligent Bio Solutions from a “hold” rating to a “sell” rating in a report on Friday, September 26th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has a consensus rating of “Sell”.

Intelligent Bio Solutions Stock Up 5.0%

NASDAQ INBS opened at $1.15 on Wednesday. The company has a market cap of $10.39 million, a price-to-earnings ratio of -0.56 and a beta of 4.49. Intelligent Bio Solutions has a 52 week low of $1.01 and a 52 week high of $2.75. The business has a 50 day moving average price of $1.45 and a 200-day moving average price of $1.51.

Intelligent Bio Solutions (NASDAQ:INBS) last released its quarterly earnings data on Friday, August 15th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.25). The firm had revenue of $0.84 million for the quarter, compared to the consensus estimate of $4.30 million. Intelligent Bio Solutions had a negative net margin of 346.22% and a negative return on equity of 231.13%. On average, equities research analysts anticipate that Intelligent Bio Solutions will post -1.25 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Intelligent Bio Solutions stock. Altium Capital Management LLC acquired a new position in Intelligent Bio Solutions Inc. (NASDAQ:INBS) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 149,252 shares of the company’s stock, valued at approximately $215,000. Intelligent Bio Solutions comprises about 0.5% of Altium Capital Management LLC’s investment portfolio, making the stock its 17th largest position. Altium Capital Management LLC owned about 2.19% of Intelligent Bio Solutions as of its most recent SEC filing. Hedge funds and other institutional investors own 32.97% of the company’s stock.

Intelligent Bio Solutions Company Profile

Intelligent Bio Solutions Inc, a medical technology company, developing non-invasive, real-time monitoring, and diagnostic tests for patients and their primary health practitioners. It offers saliva glucose biosensor for diabetes management that measures glucose in saliva. The company also provides intelligent fingerprinting drug screening system, a revolutionizing portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields; and biosensor platform for biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities.